None
SEDAR Interim Financial Statements
TTI · Price
[
{
"companyName": "Thiogenesis Therapeutics, Corp.",
"reportingPeriodEnd": "2025-09-30",
"reportStatus": "Unaudited",
"auditorName": null,
"auditorKeyMatters": [],
"balanceSheet": {
"currentAssets": {
"cashAndCashEquivalents": 3502183,
"accountsReceivable": 68123,
"prepaidExpenses": 54919,
"totalCurrentAssets": 3625225
},
"totalAssets": 3625225,
"currentLiabilities": {
"accountsPayableAndAccruedLiabilities": 1471940,
"totalCurrentLiabilities": 1471940
},
"shareholdersEquity": {
"shareCapital": 19912164,
"reserves": 2296421,
"accumulatedOtherComprehensiveLoss": -77301,
"accumulatedDeficit": -19977999,
"totalShareholdersEquity": 2153285
},
"totalLiabilitiesAndShareholdersEquity": 3625225,
"cashPerShare": 0.0737,
"workingCapitalPerShare": 0.0453
},
"incomeStatement": {
"threeMonthsEndedSep302025": {
"researchAndDevelopment": 1922572,
"generalAndAdministrative": 471840,
"totalOperatingExpenses": 2394412,
"interestIncome": -6450,
"gainLossOnForeignExchange": -4001,
"totalOtherIncomeExpenses": -10451,
"netLoss": 2383961,
"foreignCurrencyTranslation": 28861,
"totalOtherComprehensiveIncomeLoss": 28861,
"netLossFromOperationsAndOtherComprehensiveLoss": 2412822,
"netLossPerShareBasicAndDiluted": -0.05,
"weightedAverageSharesOutstandingBasicAndDiluted": 50093098
},
"threeMonthsEndedSep302024": {
"researchAndDevelopment": 404857,
"generalAndAdministrative": 272925,
"totalOperatingExpenses": 677782,
"interestIncome": -48617,
"gainLossOnForeignExchange": 27691,
"totalOtherIncomeExpenses": -20926,
"netLoss": 656856,
"foreignCurrencyTranslation": -4685,
"totalOtherComprehensiveIncomeLoss": -4685,
"netLossFromOperationsAndOtherComprehensiveLoss": 652171,
"netLossPerShareBasicAndDiluted": -0.01,
"weightedAverageSharesOutstandingBasicAndDiluted": 45500652
},
"nineMonthsEndedSep302025": {
"researchAndDevelopment": 4502132,
"generalAndAdministrative": 1162178,
"totalOperatingExpenses": 5664310,
"interestIncome": -44306,
"gainLossOnForeignExchange": 74235,
"totalOtherIncomeExpenses": 29929,
"netLoss": 5694239,
"foreignCurrencyTranslation": 31298,
"totalOtherComprehensiveIncomeLoss": 31298,
"netLossFromOperationsAndOtherComprehensiveLoss": 5725537,
"netLossPerShareBasicAndDiluted": -0.12,
"weightedAverageSharesOutstandingBasicAndDiluted": 47488444
},
"nineMonthsEndedSep302024": {
"researchAndDevelopment": 1444844,
"generalAndAdministrative": 817972,
"totalOperatingExpenses": 2262816,
"interestIncome": -165936,
"gainLossOnForeignExchange": -78131,
"totalOtherIncomeExpenses": -244067,
"netLoss": 2018749,
"foreignCurrencyTranslation": 16802,
"totalOtherComprehensiveIncomeLoss": 16802,
"netLossFromOperationsAndOtherComprehensiveLoss": 2035551,
"netLossPerShareBasicAndDiluted": -0.04,
"weightedAverageSharesOutstandingBasicAndDiluted": 45229104
}
},
"cashFlowStatement": {
"nineMonthsEndedSep302025": {
"netLoss": -5694239,
"stockBasedCompensation": 641700,
"changesInAccountsReceivable": 19805,
"changesInPrepaidExpenses": -7323,
"changesInAccountsPayableAndAccruedLiabilities": 914064,
"netCashUsedInOperatingActivities": -4125993,
"privatePlacementOfCommonSharesNet": 3811610,
"proceedsFromExerciseOfWarrants": 0,
"proceedsFromExerciseOfFindersOptions": 0,
"netCashProvidedByFinancingActivities": 3811610,
"effectOfExchangeRateChangesOnCash": -31298,
"decreaseInCashAndCashEquivalents": -345681,
"cashAndCashEquivalentsBeginningOfPeriod": 3847864,
"cashAndCashEquivalentsEndOfPeriod": 3502183
},
"nineMonthsEndedSep302024": {
"netLoss": -2018749,
"stockBasedCompensation": 183549,
"changesInAccountsReceivable": 11773,
"changesInPrepaidExpenses": 48377,
"changesInAccountsPayableAndAccruedLiabilities": -1606945,
"netCashUsedInOperatingActivities": -3381995,
"privatePlacementOfCommonSharesNet": 0,
"proceedsFromExerciseOfWarrants": 462500,
"proceedsFromExerciseOfFindersOptions": 7000,
"netCashProvidedByFinancingActivities": 469500,
"effectOfExchangeRateChangesOnCash": -16802,
"decreaseInCashAndCashEquivalents": -2929297,
"cashAndCashEquivalentsBeginningOfPeriod": 7076308,
"cashAndCashEquivalentsEndOfPeriod": 4147011
}
},
"investmentsAndOtherAssets": [],
"shareStructure": {
"authorizedShares": "Unlimited common shares",
"issuedShares": 51835956,
"classesOfShares": ["common shares"],
"warrants": [
{
"number": 762720,
"exercisePrice": 0.75,
"expiryDate": "2027-07-30"
}
],
"options": [
{
"number": 1950000,
"exercisePrice": 0.35,
"expiryDate": "2032-03-31"
},
{
"number": 150000,
"exercisePrice": 0.5,
"expiryDate": "2032-08-31"
},
{
"number": 450000,
"exercisePrice": 0.6,
"expiryDate": "2032-12-08"
},
{
"number": 50000,
"exercisePrice": 0.8,
"expiryDate": "2028-10-31"
},
{
"number": 228247,
"exercisePrice": 0.75,
"expiryDate": "2025-12-15"
},
{
"number": 181335,
"exercisePrice": 0.75,
"expiryDate": "2025-12-19"
},
{
"number": 325000,
"exercisePrice": 0.75,
"expiryDate": "2029-01-15"
},
{
"number": 100000,
"exercisePrice": 0.7,
"expiryDate": "2027-10-01"
},
{
"number": 100000,
"exercisePrice": 0.64,
"expiryDate": "2028-02-15"
},
{
"number": 450000,
"exercisePrice": 0.73,
"expiryDate": "2028-05-23"
},
{
"number": 400000,
"exercisePrice": 0.77,
"expiryDate": "2030-06-11"
},
{
"number": 150000,
"exercisePrice": 0.75,
"expiryDate": "2030-09-10"
}
],
"rightsConvertibleInstruments": null
},
"managementCompensation": {
"currency": "CAD",
"periods": [
{
"period": "For the Three Months Ended September 30, 2025",
"salariesAndConsultingFees": 155616,
"stockBasedCompensation": 182133,
"directorFees": 26173,
"total": 363922
},
{
"period": "For the Nine Months Ended September 30, 2025",
"salariesAndConsultingFees": 464130,
"stockBasedCompensation": 444526,
"directorFees": 77149,
"total": 985805
},
{
"period": "For the Three Months Ended September 30, 2024",
"salariesAndConsultingFees": 148603,
"stockBasedCompensation": 10591,
"directorFees": 25766,
"total": 184960
},
{
"period": "For the Nine Months Ended September 30, 2024",
"salariesAndConsultingFees": 443061,
"stockBasedCompensation": 59408,
"directorFees": 74713,
"total": 577182
}
],
"namedIndividuals": [],
"otherRelatedPartyTransactions": []
},
"subsequentEvents": []
}
]
More from Thiogenesis Therapeutics Corp
Jun 03, 2026 · 06:01